The latest price target for Mineralys Therapeutics (NASDAQ:MLYS) was reported by HC Wainwright & Co. on November 12, 2024. The analyst firm set a price target for $30.00 expecting MLYS to rise to within 12 months (a possible 133.10% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Mineralys Therapeutics (NASDAQ:MLYS) was provided by HC Wainwright & Co., and Mineralys Therapeutics reiterated their buy rating.

There is no last upgrade for Mineralys Therapeutics

There is no last downgrade for Mineralys Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mineralys Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mineralys Therapeutics was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.

While ratings are subjective and will change, the latest Mineralys Therapeutics (MLYS) rating was a reiterated with a price target of $30.00 to $30.00. The current price Mineralys Therapeutics (MLYS) is trading at is $12.87, which is out of the analyst’s predicted range.